Highest-materiality recent filing
Precision BioSciences doses first patient in Phase 1/2 FUNCTION-DMD gene editing trial
First patient dosed with PBGENE-DMD, first clinical gene-editing program for DMD, at Arkansas Children's Hospital.
Liver biopsy showed 1-log reduction in cccDNA with <1% remaining after two PBGENE-HBV doses.
PBGENE-HBV shows 1-log cccDNA reduction; DMD trial activates second site
PBGENE-HBV in ELIMINATE-B study demonstrated 1-log (10-fold) reduction in cccDNA-derived transcripts from liver biopsy.
Liver biopsy data show 1-log reduction in cccDNA transcripts after two doses at 0.4 mg/kg; indels inactivate remaining <1%.
Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing
Net loss $18.4M ($0.75/share) vs $20.6M loss ($2.21/share) in Q1 2025.
Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).
FDA clears Precision BioSciences' IND for PBGENE-DMD gene editing therapy for DMD
FDA Study May Proceed allows initiation of clinical trial site activation for Phase 1/2 FUNCTION-DMD study in ambulatory DMD patients.
Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.
Precision BioSciences prices $75M underwritten offering of common stock and warrants
Offering: 10.8M shares + 1.4M pre-funded warrants at $6.14/$6.139995 per unit; gross proceeds ~$75M.
Phase 1 ELIMINATE-B trial: 9 patients across 0.2, 0.4, 0.8 mg/kg doses (22 total administrations); no dose-limiting toxicities observed.
Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.
Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients
Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).
Precision BioSciences' PBGENE-HBV shows durable HBsAg reduction in Phase 1; cash runway to H2 2027
Cohort 1 (0.2 mg/kg): well-tolerated; best HBsAg reductions of 56%, 69%, and 47% across three patients.
Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated
Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.
Precision BioSciences accelerates PBGENE-DMD, plans IND/CTA in 2025; pauses PBGENE-3243
PBGENE-DMD is a first-in-class in vivo gene editing approach targeting exons 45-55; up to 60% of DMD patients carry mutations in this hotspot region.
Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction
Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.
Precision BioSciences Q3 revenue $0.6M, net loss $16.4M; PBGENE-HBV enters clinic
Revenue $0.6M down from $13.1M YoY; net loss $16.4M ($2.25/share) vs $8.1M loss in Q3 2023.
Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova
Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).
Alan List, CMO, retiring effective Sept 13, 2024; will transition to clinical consultant at $325/hour and remain on SAB.
Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024
Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.
Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026
Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.
Prevail (Lilly sub) terminated collaboration without cause effective July 10, 2024; Precision exercised reversion option to regain programs.
Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026
FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.
Precision BioSciences prices $40M public offering of 2.5M shares and warrants at $16/unit
Offering of 2,500,000 common shares and warrants to purchase another 2,500,000 shares at $16.00 per unit.
Approximately 68.34% of common shares represented at special meeting on January 18, 2024.
Precision grants TG Therapeutics exclusive license for non-oncology applications of azer-cel, receiving $17.5M in upfront and near-term payments.
Precision BioSciences Q3 2023 net loss narrows to $8.1M; cash runway through 2025
Q3 2023 revenue $13.1M (up from $7.4M YoY); net loss $8.1M ($0.07/share) vs $23.9M ($0.22/share) in Q3 2022.
Transfer from Nasdaq Global Select to Nasdaq Capital Market effective Oct 26, 2023; ticker remains DTIL.
Precision BioSciences unveils mitoARCUS program PBGENE-PMM; HBV program on track for 2024 filing
Announced PBGENE-PMM, first mitoARCUS candidate targeting m.3243 primary mitochondrial myopathy; CTA/IND submission targeted for 2025.
Precision BioSells CAR T manufacturing to Imugene for $8M cash and $13M convertible notes
Imugene acquired CAR T manufacturing infrastructure, including MCAT facility, for $8M cash and $13M in 1-year non-interest-bearing convertible notes.
Upfront consideration of $21M ($8M cash + $13M convertible notes); $8M milestone upon Phase 1b completion.
Precision BioSciences Q2 net loss narrows to $11.9M; FDA clarity on azer-cel; cash through Q1 2025
Net loss of $11.9M ($0.10 per share) vs $31.0M ($0.46) in Q2 2022; revenue $19.8M from $3.8M on Prevail amendment.
On January 23, 2025, Sam Wadsworth, Ph.D., notified Precision BioSciences, Inc. (the “Company”) of his intention to retire from service on company boards and resigned from the Company’s Board of Directors.
On September 9, 2024, Alan List, M.D., the Company’s Chief Medical Officer, notified Precision BioSciences, Inc. (the “Company”) that he will be retiring from the Company, effective September 13, 2024.
On August 31, 2023, Shane Barton notified Precision BioSciences, Inc. (the “Company”) of his resignation as the Company’s Vice President and Corporate Controller, effective September 15, 2023
On September 6, 2023, the Company’s Board of Directors designated Alex Kelly, the Company’s Chief Financial Officer and principal financial officer, to also serve as the Company’s principal accounting officer effective upon Mr. Barton’s departure.
On February 22, 2023, Derek Jantz, Ph.D. notified Precision BioSciences, Inc. (the “Company” or “Precision”) of his intentions to gradually step away from his current day-to-day responsibilities at Precision to pursue other personal and professional interests while continuing to support the Company’s external relationships, including with existing and potential business development partners.
On November 5, 2022, Dr. Raymond Schinazi informed the Board of Directors (the 'Board') of Precision BioSciences, Inc. (the 'Company' or 'Precision') that he was resigning from the Board, as well as his roles as Chair of the Board’s Nominating and Corporate Governance Committee and a member of the Board’s Compensation Committee and Science and Technology Committee, with immediate effect.
Dr. Derek Jantz informed the Board of Directors (the "Board") that he was resigning from the Board with immediate effect
Jeff Smith, Ph.D., co-founder, will become Chief Research Officer reporting to the Chief Executive Officer from his prior role as Chief Technology Officer, with responsibility for management and direction of the Company’s research function.
the Board of Directors (the “Board”) of Precision BioSciences, Inc. (the “Company”) appointed Melinda Brown to serve as a Class III director on the Company’s Board and as Chair of the Audit Committee of the Board.
Shari Lisa Piré to serve as a Class III director on the Company’s Board and as a member of the Nominating and Corporate Governance Committee of the Board
Samuel Wadsworth, Ph.D. to serve as a Class II director on the Company’s Board and as a member of the Science and Technology Committee of the Board
Mr. Amoroso succeeds Mathew Kane who, as previously reported, agreed to cease serving in both capacities effective with his successor’s commencement of service with the Company and to serve as a non-employee advisor to the Company through October 1, 2022
Max materiality 0.90 · Median 0.70 · Most common event other_material